When it comes to neuropsychiatric drugs, Novartis peaked in 2011. In that year sales of its therapies that broadly fall into the categories of cognitive, mood and movement disorders topped $3bn; since then these revenues have fallen dramatically. But the company appears to be getting back into this area judging by its latest deal, in which it bought Cadent Therapeutics for $210m up front. Cadent’s pipeline encompasses CAD-9303, an NMDAr positive allosteric modulator scheduled to enter phase II trials in schizophrenia next year, and CAD-1883, a modulator of SK channels, whose phase II trial in spinocerebellar ataxia is currently on hold owing to the Covid-19 pandemic. Cadent is also developing MIJ821, a phase II-stage NMDAr negative modulator which was licensed to Novartis in 2015 by Luc Therapeutics, one of the two companies from which Cadent was subsequently formed. Other than MIJ821 Novartis’s own pipeline contains just one clinical-stage neuropsychiatric project, LMI070, an SMN2 gene splicing modulator in phase II for depression. Still, Novartis is big in multiple sclerosis, with Kesimpta and Mayzent forecast to sell nearly $3.4bn between them in 2026, EvaluatePharma consensus shows. Perhaps the Swiss firm believes its MS salesforce can handle its new CNS therapies, too.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.